In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
Bacterial resistance to antimicrobial agents is an ever-increasing problem. The in-vitro activity of sparfloxacin compared with that of currently available antimicrobial agents against pathogens implicated in respiratory tract infections is reviewed. Sparfloxacin is a fluoroquinolone active against both penicillin-susceptible and -resistant strains of Streptococcus pneumoniae. It is also active against many other respiratory tract pathogens and may be a suitable alternative for empirical therapy of community-acquired respiratory tract infections.
Baquero
F
F
Department of Microbiology, Ramón y Cajal Hospital, National Institute of Health (INSALUD), Madrid, Spain.
Cantón
R
R
D000890:Anti-Infective Agents / Q000494:pharmacology*; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C061363:sparfloxacin